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Abstract
Background: In 2010, Me´decins Sans Frontie`res (MSF) investigated reports of high mortality in young children in Zamfara
State, Nigeria, leading to confirmation of villages with widespread acute severe lead poisoning. In a retrospective analysis,
we aimed to determine venous blood lead level (VBLL) thresholds and risk factors for encephalopathy using MSF
programmatic data from the first year of the outbreak response.
Methods and Findings: We included children aged #5 years with VBLL $45 mg/dL before any chelation and recorded
neurological status. Odds ratios (OR) for neurological features were estimated; the final model was adjusted for age and
baseline VBLL, using random effects for village of residence. 972 children met inclusion criteria: 885 (91%) had no
neurological features; 34 (4%) had severe features; 47 (5%) had reported recent seizures; and six (1%) had other neurological
abnormalities. The geometric mean VBLLs for all groups with neurological features were .100 mg/dL vs 65.9 mg/dL for
those without neurological features. The adjusted OR for neurological features increased with increasing VBLL: from 2.75,
95%CI 1.27–5.98 (80–99.9 mg/dL) to 22.95, 95%CI 10.54–49.96 ($120 mg/dL). Neurological features were associated with
younger age (OR 4.77 [95% CI 2.50–9.11] for 1–,2 years and 2.69 [95%CI 1.15–6.26] for 2–,3 years, both vs 3–5 years).
Severe neurological features were seen at VBLL ,105 mg/dL only in those with malaria.
Interpretation: Increasing VBLL (from $80 mg/dL) and age 1–,3 years were strongly associated with neurological features;
in those tested for malaria, a positive test was also strongly associated. These factors will help clinicians managing children
with lead poisoning in prioritising therapy and developing chelation protocols.
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Introduction
Lead poisoning is not a new phenomenon. Though debate
continues as to whether it was described by Hippocrates [1], and
the hypothesis that it contributed to the fall of the Roman Empire
remains in dispute [2,3], humans have been exposed to lead as a
toxicant since at least the start of industrialisation. It continues to
be a significant cause of morbidity. In 2004, lead poisoning
accounted for about 0.6% of the global burden of disease and 9
million disability-adjusted-life-years [4]. Lead affects mechanisms
as diverse as energy metabolism, apoptosis, cell adhesion,
intercellular and intracellular signalling, protein maturation, and
genetic regulation [4]. As a result, lead poisoning causes a
continuum of sub-clinical and clinical features including hyper-
tension [5], nephropathy [6], infertility [7], anaemia, behavioural
changes including violence [8], and decreased IQ (intelligence
quotient) [9]; as well as severe manifestations such as acute
encephalopathy and death [10,11,12].
In resource-rich nations, deaths from lead encephalopathy are a
largely historical phenomenon. Hundreds of children died from
lead poisoning in the USA in the first half of the 20th Century
when lead use was widespread [13]. Lead-related deaths in US
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e93716
cities in the 1950s and 1960s were primarily related to lead paint
ingestion [11,12]. One Baltimore hospital reported 36 cases of
severe lead encephalopathy between 1954 and 1956 [14], while 38
cases were reported in Chicago between 1959 and 1963 [15] -
examples of a broader problem that reported figures likely grossly
underestimate. The last recorded death from lead encephalopathy
in the USA was in 2006 [16], preceded by one in 2000 that was
itself the first since 1990 [17]. Reports of lead-related deaths are
uncommon in resource-poor settings, and mostly detected though
outbreaks, such as the 18 deaths in Senegal linked to lead acid
battery recycling in 2007 [18].
In March 2010, a Me´decins Sans Frontie`res (MSF) disease
surveillance team in Zamfara State, northern Nigeria, was
contacted by leaders and health staff of a local village with reports
of high mortality in young children following an unknown illness.
MSF was invited to assist in investigating these reports by the state
Ministry of Health. MSF carried out an initial assessment and
rapidly assembled a dedicated response team and 24-hour care in
the village clinic. Children presented with sudden onset of
abdominal pain and/or vomiting, intractable seizures with or
without fever, then sometimes rapid progression to death.
Symptoms were unresponsive to initial treatment by the MSF
team for common endemic diseases such as malaria and
meningitis, and anti-convulsants had little effect. Over 2 months
until 17 May 2010, nearly 300 children aged #5 years presented
in four villages with these symptoms with a mortality of 48%.
There were anecdotal reports of a recent increase in small-scale
ore processing with dry-milling to extract gold. An outbreak of
severe lead poisoning was confirmed [19,20,21]. Initially, seven
rural villages were identified as extremely lead contaminated due
to dust dispersed by artisanal mining activities within the villages,
with an estimated 3000 children aged #5 years at risk of lead
poisoning. Identification activities included active case finding by
MSF and investigations by State Ministry of Health with Nigeria
Centre for Disease Control and US Centers for Disease Control
and Prevention (CDC, USA), and environmental testing by
TerraGraphics Environmental Engineering and CDC, USA
[22]. The true scale of contamination in the region remains
unclear [23]. Extensive environmental remediation has been
undertaken [20]. Health promotion has focused on removing the
lead exposure harming children by relocating ore processing
activities and minimising further lead contamination of the
villages.
The focus of the MSF emergency medical response was clinical
lead surveillance and chelation therapy. All children aged #5
years from the seven villages where remediation was taking place
were offered screening by MSF as their villages were remediated.
Treatment in the absence of environmental remediation has
limited impact, so screening in unremediated villages was
considered futile. Children with venous BLL (VBLL) $45 mg/
dL (the MSF protocol and CDC recommended chelation
threshold) from remediated villages [24] were offered chelation
therapy, the outcomes of which will be reported separately.
Children from unremediated villages presenting to an MSF facility
with signs of encephalopathy and therefore at immediate risk of
death were tested and treated with chelation therapy if required,
and discharged to an uncontaminated location when possible.
Although there has been some characterisation of the clinical
pattern of lead toxicity [4,10,25] and the VBLL threshold for
encephalopathy is often stated to be in the range of 70–100 mg/dL
[4,26], there are limited data on the VBLL threshold above which
life-threatening effects including encephalopathy are likely to
occur in children [10,25,27,28]. In this paper we describe nearly
1000 lead exposed children with VBLL $45 mg/dL, and the
clinical and demographic characteristics associated with neuro-
logical features using basic clinical examination. This is the largest
reported retrospective analysis of data from children#5 years with
VBLL in this range.
Methods
For the period June 2010 to the end of June 2011, we included
all children aged #5 years with a first-ever VBLL $45 mg/dL
recorded before chelation therapy and whose neurological status
was recorded within 7 days of this VBLL. Screening and treatment
were provided by MSF. Children were identified via an MSF
door-to-door census that detailed children aged #5 years living in
each residential compound. Screening for enrolment to the MSF
chelation programme included a brief clinical history and
examination, with particular attention to neurological status.
Neurological assessment included history of seizures, change in
behaviour, delay or loss of developmental milestones, peripheral
neuropathies, gait, assessment of reflexes, and level of conscious-
ness (alert/voice/pain/unresponsive [AVPU] assessment scale
[29]). Detailed demographic and clinical data were recorded on
standardised forms by medical staff. Only key data were entered
into an electronic database, including enrolment data: AVPU,
neurological manifestations (summarised as none, present [not
severe], severe), recent seizure history (yes/no). In addition, key
inpatient data were entered: seizures during hospitalisation (yes/
no; if yes, change during admission) and other neurological
symptoms during hospitalisation (none, present [not severe],
severe; if present, change during admission). Neurological status
for this analysis was described by a composite measure of
neurological signs or symptoms and AVPU as severe neurological
features (1), presumptive seizures (2), mild neurological features (3),
or no neurological features identified (4) (Table 1), with categories
1–3 combined as ‘‘any neurological features’’.
VBLL was measured using the Lead Care II point-of-care
analyser (Magellan Biosciences, Chelmsford Massachusetts), using
manufacturer-recommended protocols, with samples testing above
the upper limit of 65 mg/dL retested using a dilution method
developed with CDC and described elsewhere [30]. Regular
quality control for VBLL was provided by CDC, USA, using
inductively-coupled plasma mass spectrometry (ICPMS): point-of-
care values of 120 clinical samples (13% diluted in project from
.65 mg/dL) were on average 4.0 mg/dL lower than ICPMS
(limits of agreement [31] 219.7 mg/dL to +11.7 mg/dL). VBLL
results were categorised: 45–64, 65–79, 80–99, 100–119, 120–199,
$200 mg/dL. Haemoglobin was measured on all venous samples
by the HemoCue Hb 301 point-of-care testing system (HemoCue,
Angelholm, Sweden) prior to 22nd November 2010, and by the
Sysmex Automated Hematology Analyzer, KX-21N (Sysmex,
Hyogo, Japan) after this date. Venous samples were also used to
assess alanine transaminase (ALT) (HumaLyser 2000 [Human,
Wiesbaden, Germany]). Where symptoms such as fever were
suggestive of malaria, a malaria rapid diagnostic test (RDT) was
performed (HRP-2 tests as the endemic cases and seasonal
outbreaks are almost exclusively due to Plasmodium falciparum).
Prevalence levels in children between the ages of 6 months to 59
months in the area are 48.2% [32]. Children with positive test
results were immediately treated with artemisinin-based combi-
nation therapy (ACT) for uncomplicated malaria and artemether
for severe malaria.
Haematological and biochemical parameters were categorised
[33]: haemoglobin (g/dL) low (,10 if ,2 years old, ,11 if 2–5
years), high (.13 if ,2 years, .14 if 2–5 years), or normal; ALT
(U/L) normal (0–42), mildly elevated (.42–100), moderately
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elevated (.100–1000), or severely elevated (.1000). MUAC (mid-
upper arm circumference) for nutritional status was recorded as
green ($135 mm), yellow ($125 to ,135 mm), orange ($110 to
,125 mm; moderately malnourished) or red (,110 mm; severely
malnourished) for children aged $6 months, or not applicable for
infants ,6 months. Age at time of VBLL was grouped as 0–,6
months, 6–,12 months, 1–,2 years, 2–,3 years, 3–5 years,
based on USA Environmental Protection Agency guidance
regarding behavioural and physiological development stages for
environmental assessment [34].
Selected clinical and laboratory data were routinely entered into
an electronic database specifically designed (by JG) to support
patient care and programme management. Data were analysed
using STATA 10.1 (StataCorp, Texas, USA). Baseline character-
istics were described as counts and percentages of patients in each
category and compared with chi-squared or Fisher’s exact tests
unless a high proportion of data was missing. VBLL by
neurological status category was calculated as geometric means
with 95% confidence intervals (95% CI) due to non-normally
distributed data, accommodating clustering by village of residence
by using robust standard errors. Log VBLL values by neurological
status categories were compared by Analysis of Variance with
Scheffe test between groups. Odds ratios (OR) for any neurological
features (compared to none) were estimated for the following
variables based on review of descriptive data, completeness and
plausibility, with random effects (for village of residence as a
variable potentially incorporating various unmeasured factors such
as level of environmental contamination): gender; age at time of
VBLL; baseline VBLL category; nutritional status (MUAC); and
haemoglobin. A multivariable multi-level logistic regression
random effects model to estimate adjusted OR of the outcome
of any neurological symptoms included factors significant at
p,0.10 in the unadjusted analysis or with plausible epidemiolog-
ical or biological association. Backward selection was used to
choose prognostic variables for the final model, discarding those
no longer associated (p.0.10) with the outcome after adjustment
for other variables. P-values were calculated for the strength of
association of each variable with the outcome using Wald tests,
and the VBLL categorical variable assessed as continuous to test
for trend. Interaction was not plausible with the retained variables.
The sensitivity of the model was assessed for severity of
neurological features. The role of malaria was assessed in patients
who had been tested for malaria due to symptoms (33%), adjusting
for age and VBLL.
Ethics statement
This study met the standards set by the independent MSF
Ethics Review Board for retrospective analyses of routinely
collected programmatic data [35], here being data collected to
facilitate life-saving clinical care. These standards include, but are
not limited to, assurances of confidentiality, involvement of local
partners and minimal harm to patients. Coded identification
numbers were used and personal identifiers and all unnecessary
data were removed from the dataset. Review of anonymous
routinely collected programmatic data does not constitute research
under the National Health Research Ethics Committee of Nigeria
guidelines. CDC USA staff involvement did not require CDC
Human Subject Review as CDC personnel were not involved in
treating patients.
Results
Patient characteristics
Between 1 June 2010 and 30 June 2011 approximately 95% of
children in the seven remediated villages were screened; 972
children met the inclusion criteria (Figure 1). Among another 160
children meeting age, VBLL and date criteria, but with
inadequate record of neurological status in their clinical file,
geometric mean VBLL was lower than for those with recorded
neurological status (65.3 mg/dL [95%CI 61.5–69.4] vs 79.4
[95%CI 62.6–100.7]; p = 0.010), however there was no difference
in the proportion female (46.9% vs 49.2%; p= 0.59), or the age
distribution (p = 0.87). Among the 972 children included, 340
(35%) had a VBLL $80 mg/dL. The maximum VBLL recorded
was 708 mg/dL. 73 (8%) children had a VBLL 120–199 mg/dL
and 27 (3%) had VBLL $200 mg/dL (Table 2). Proportionally
more children aged 1–,2years had VBLL $120 mg/dL than in
the other age groups (25% [39/159] vs 7% for all other ages
combined [61/813; all other age groups were each separately
,13%]; p,0.001) (Table 2). 14 children had died by 30 June
2011; lead poisoning was likely a primary cause in five of these
deaths as these children had recent high VBLL (104–460 mg/dL)
and symptoms consistent with lead encephalopathy, with no other
obvious cause of death.
Most (885 [91%]) children had no neurological features, 34
(4%) had seizures witnessed by medical staff and/or reduced level
of consciousness, 47 (5%) had a guardian-reported history of
recent seizures but no altered consciousness on presentation, and
six (1%) displayed some other signs of neurological abnormality
(Table 3). The geometric mean VBLL for all groups with
neurological features was .100 mg/dL (157.6 mg/dL for mild
neurological features, 106.9 mg/dL for presumptive seizures and
170.1 mg/dL for severe neurological features) compared with
65.9 mg/dL for those without neurological features (Table 3;
Figure 2). The range of VBLL in each group was wide, such that
children with no neurological features at first presentation had
Table 1. Neurological status categories and definitions.
Neurological status category Definition
1 Severe neurological features: Seizures witnessed by medical staff; and/or altered consciousness (an AVPU of V or P or U).
2 Presumptive seizures: A guardian’s report of recent (within the past few days) seizure activity and an AVPU of A on presentation; but no
seizures witnessed by medical staff.
3 Mild neurological features: Any neurological signs or symptoms noted by medical staff but without reported history or witnessed seizure; and an
AVPU of A on presentation.*
4 No neurological features identified: No significant neurological signs or symptoms identified on brief clinical examination by the initial treating doctor; and
no history of recent seizures.
*Noted abnormalities were hypo-reflexia, inconsolable crying, agitation, and decreased mobility.
‘‘Any neurological features’’ = categories 1+2+3.
doi:10.1371/journal.pone.0093716.t001
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VBLLs up to 345 mg/dL, and children with neurological features
had VBLL as low as 47 mg/dL (Table 3); only children with
concurrent malaria had severe neurological features below VBLL
105 mg/dL.
Within age groups, neurological features were most common in
1–,2 year olds (25% vs 6% for other ages; p,0.001). 233 (72%)
of 325 children tested for malaria had a positive RDT result. A
positive malaria test was more common in children with
neurological features than in those without (82% [56/68] vs
69% [177/257], respectively; p= 0.034) (Table 3); 19 children
with neurological features did not have a malaria test recorded. A
positive malaria test was more common in children with VBLL
,80 mg/dL (n= 194 tested for malaria) who had any neurological
features (95% [21/22]) compared to those without features (72%
[123/172]; p= 0.016), but not significantly different with VBLL
$80 mg/dL (76% [35/46] with neurological features vs 64% [54/
85] without; p = 0.14). Poor nutritional status (malnourished
[MUAC red or orange] vs not) was more common in children
with neurological features than in those without (14% [9/66] vs
4% [31/700], respectively; p = 0.005). Most (75%) children had
low haemoglobin regardless of neurological features; a non-
significantly higher proportion of children with no neurological
features had normal haemoglobin levels (24% vs 18%; p= 0.23). A
high proportion (24%) of children had no ALT results recorded; a
low proportion of children had elevated ALT levels (9%), none
were severely elevated (Table 3).
Factors associated with neurological features
In logistic regression (unadjusted OR, random effects for village
of residence), presentation with any neurological features was not
associated with gender (OR=1.08, 95%CI 0.68–1.72; p = 0.73),
or low haemoglobin (OR=1.39, 95%CI 0.77–2.50; p= 0.27), but
was associated with age (highest for 1–,2 years [OR=9.42,
95%CI 5.23–16.96; p,0.001] compared with 3–5 years), increas-
ing VBLL (test for trend p,0.001, starting from 80.0–99.9 mg/dL
with OR=3.06, 95%CI 1.43–6.53), and moderate-severe malnu-
trition (OR=4.76, 95%CI 2.02–11.31; p,0.001). The final
multivariate analysis retained only age and VBLL as strongly
associated with any neurological features after adjustment for the
other factors and random effects for village (both p,0.001).
Children aged 1–,2 years had the highest odds of neurological
features compared with children age 3–5 years (adjusted OR 4.77,
95%CI 2.50–9.11); age 2–,3 years was also associated with
neurological features (adjusted OR 2.69, 95%CI 1.15–6.26)
compared with children age 3–5 years. Increasing VBLL
Figure 1. Inclusion and exclusion criteria. VBLL = venous blood lead level.
doi:10.1371/journal.pone.0093716.g001
Table 2. First-ever pre-chelation VBLL test (in categories, mg/dL) by age group (number and % of row).
45–64.9 65–79.9 80–99.9 100–119.9 120–199.9 200+ Total
0–,6 months 33 (65%) 5 (10%) 3 (6%) 5 (10%) 4 (8%) 1 (2%) 51 5%
6–,12 months 52 (51%) 5 (5%) 20 (20%) 14 (14%) 7 (7%) 4 (4%) 102 10%
1–,2 years 75 (47%) 4 (3%) 23 (14%) 18 (11%) 22 (14%) 17 (11%) 159 16%
2–,3 years 53 (54%) 8 (8%) 14 (14%) 11 (11%) 11 (11%) 1 (1%) 98 10%
3–5 years 363 (65%) 34 (6%) 88 (16%) 44 (8%) 29 (5%) 4 (1%) 562 58%
Total 576 (59%) 56 (6%) 148 (15%) 92 (9%) 73 (8%) 27 (3%) 972
VBLL = venous blood lead level.
doi:10.1371/journal.pone.0093716.t002
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(compared with the reference category of 45–64.9 mg/dL) was
strongly associated with increased odds of neurological features
(test for trend p,0.001): adjusted OR 2.75, 95%CI 1.27–5.98
(VBLL 80–99.9 mg/dL); 3.84, 95%CI 1.62–9.09 (100–119.9 mg/
dL); and 22.95, 95%CI 10.54–49.96 ($120 mg/dL) (Table 4).
A sensitivity analysis using only the outcome of severe
neurological features compared with all other patients gave similar
overall results. The association with VBLL was stronger and the
trend robust (test for trend p,0.001), but significant only from
100–119.9 mg/dL (adjusted OR 7.35, 95%CI 2.02–26.79; for
VBLL$120 mg/dL adjusted OR 23.96, 95%CI 7.33–78.31). The
adjusted OR were also higher for all ages with the largest
associations for children aged 1–,3 years (OR.6 for both 1–
,2 y and 1–,3 y) compared with children aged 3–5 years.
Severe neurological features in children with a positive malaria
RDT result were seen at VBLL as low as 50 mg/dL, while in those
with a negative RDT the lowest VBLL with severe neurological
features was 105 mg/dL, and in the one child with severe
neurological features and no malaria test result the VBLL was
293 mg/dL. In the 325 children with a malaria RDT result, the
unadjusted OR of a positive RDT with any neurological features
was 2.04 (95% CI 0.96–4.35; p = 0.065). After adjustment for age
and VBLL there was evidence of a strong association of malaria
with neurological features (adjusted OR=3.60, 95% CI 1.42–
9.09; p = 0.007); after adjustment for malaria, age and VBLL
showed a similar pattern of association with neurological features
as in the entire cohort, that is, highest adjusted OR in 1–,2 year
olds and increasing adjusted OR with increasing VBLL.
Discussion
The MSF programmatic data collected during the response to
the Zamfara lead poisoning disaster presents a cohort size and
severity that is unprecedented. While lead poisoning was endemic
in resource-rich countries in the early to mid-20th Century, an
acute outbreak of this magnitude has not been reported in the
literature. Chisolm et al. reported 197 children exposed to lead
including 41 cases of severe encephalopathy in 1952–1954 [12]
and Greengard et al. reported 38 severe cases in 1962 and 1963
with blood lead levels in 20 fatalities of 90–825 mg/dL [15]. More
recently, the Treatment of Lead-exposed Children (TLC) trial
group reported a cohort of 780 patients, although all had VBLL
,45 mg/dL [36] and thus are not comparable with the patients in
Zamfara. Reports in recent decades with similar numbers of
children screened for lead poisoning have been based on general
population datasets, with much lower geometric mean VBLLs,
generally ,10 mg/dL [37,38]. Media reports of lead poisoning of
hundreds of children in China in 2009 [39,40] indicated
comparatively low lead levels, with no detailed reports published
of acutely severely intoxicated children. Other recent studies have
concerned low-level endemic lead poisoning [41,42]. In the 972
children included in this analysis, the geometric mean VBLL was
79.4 mg/dL, 35% had VBLL $80 mg/dL, and 9% had some
clinically identified neurological features consistent with lead
poisoning. An additional 696 children (35% of those screened) had
first-ever VBLLs of 10–44.9 mg/dL and thus did not require
chelation (and are not reported in this analysis), such that the
range of exposure of this cohort of children is consistent with the
entire clinical and sub-clinical spectrum of lead pathophysiology.
Children with severe neurological features of altered conscious-
ness or seizures witnessed by clinical staff had significantly higher
VBLL than those with only a guardian-reported recent history of
seizures. Having any neurological feature was strongly associated
with increasing initial VBLL, with evidence of an increased OR at
a VBLL of 80–99.9 mg/dL, becoming stronger at 100–119.9 mg/
dL and larger still from 120 mg/dL. This is consistent with
previous ranges given for the threshold above which encephalop-
athy risk is increased [4,10,26], strengthened by the robust
Figure 2. Distribution of VBLL by neurological status in children #5 years, with first-ever pre-chelation VBLL $45 mg/dL. VBLL tested
from 1 June 2010 to 30 June 2011. VBLL= venous blood lead level.
doi:10.1371/journal.pone.0093716.g002
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evidence from this large cohort of poisoned children. Clinicians
managing patients with lead poisoning should take into consider-
ation the presence of neurological features and, particularly, the
potential risk of life-threatening encephalopathy at VBLL above
80 mg/dL, particularly (as discussed in more detail below) in those
with concurrent malaria.
Severe neurological features were not seen below VBLL 50 mg/
dL and in the absence of a positive malaria test, not below 105 mg/
dL. Most children with neurological features at a lower VBLL
(,80 mg/dL) also had a positive malaria test. In 325 children with
symptoms suggestive of malaria who were tested by RDT, a
positive result was independently associated with neurological
features in addition to the trend associating increasing VBLL with
neurological features. It is challenging to distinguish between
features of cerebral malaria and lead encephalopathy clinically,
and the presence of both lead and malaria were strongly associated
with neurological features. We postulate that it is also possible that
haemolysis associated with malaria increases the relative propor-
tion of free plasma lead at a given (whole blood) VBLL, increasing
the lead available to cause encephalopathy. The interaction
between malaria infection and lead toxicity is still uncertain and is
an area for future research.
Of children with no neurological features at the time of initial
examination, 31% had VBLL $80 mg/dL, comparable to the
United States National Academy of Sciences cohort [10]. Clinical
signs and symptoms varied among children with similar blood lead
levels, confirming that clinical features alone are poor predictors of
the severity of lead poisoning and the risk of long-term
Table 3. Characteristics by neurological status in children #5 years, with first-ever pre-chelation VBLL $45 mg/dL from 1 June
2010 to 30 June 2011.
No neurological
features (n =885)
Mild neurological
features (n =6)
Presumptive
seizures (n=47)
Severe
neurological
features (n =34) p-value{ All (n =972)
Geometric mean VBLL (95% CI) (mg/dL) 65.9 (59.7–72.7) 157.6 (52.1–476.3) 106.9 (76.1–150.3) 170.1 (112.0–258.2) ,0.001 79.4 (62.6–
100.7)
VBLL range (mg/dL) 45.0–345.1 49.2–708.0 46.9–531.0 50.6–459.9 45.0–708.0
VBLL $80 mg/dL, n (%) 276 (31%) 5 (83%) 32 (68%) 27 (79%) ,0.001 340 (35%)
Sex male, n (%) 450 (51%) 2 (33%) 27 (57%) 15 (44%) 0.56 494 (51%)
Age category, n (%) ,0.001
0–,6 months 48 (5%) 0 2 (4%) 1 (3%) 51 (5%)
6–,12 months 92 (10%) 1 (17%) 5 (11%) 4 (12%) 102 (10%)
1–,2 years 119 (13%) 3 (50%) 17 (37%) 20 (59%) 159 (16%)
2–,3 years 87 (10%) 1 (17%) 5 (11%) 5 (15%) 98 (10%)
3–5 years 539 (61%) 1 (17%) 18 (38%) 4 (12%) 562 (58%)
Malaria RDT, n (%)
Symptomatic; RDT negative 80 (9%) 1 (17%) 4 (9%) 7 (9%) 92 (9%)
Symptomatic; RDT positive 177 (20%) 4 (67%) 26 (55%) 26 (76%) 233 (24%)
Asymptomatic/missing* 628 (71%) 1 (17%) 17 (36%) 1 (3%) 647 (67%)
Nutritional status (MUAC), n (%) 0.045
Red (,110 mm) 8 (1%) 0 2 (4%) 1 (3%) 11 (1%)
Orange ($110 ,125 mm) 23 (3%) 0 5 (10%) 1 (3%) 29 (3%)
Yellow ($125 ,135 mm) 56 (6%) 1 (17%) 3 (6%) 5 (15%) 65 (7%)
Green ($135 mm) 613 (69%) 3 (05%) 27 (57%) 18 (53%) 661 (68%)
Not applicable (,6 m old) 48 (5%) 0 2 (4%) 1 (3%) 51 (5%)
Missing ($6 m old) 137 (15%) 2 (33%) 8 (17%) 8 (24%) 155 (16%)
Laboratory tests at time of VBLL, n (%)
Normal haemoglobin (g/dL) 213 (24%) 0 13 (28%) 3 (9%) 0.050 229 (24%)
Low (,10 if ,2 y; ,11 if 2–5 y) 664 (75%) 6 (100%) 33 (70%) 30 (88%) 733 (75%)
High (.13 if ,2 y; .14 if 2–5 y) 2 (0%) 0 1 (2%) 1 (3%) 4 (0%)
Missing 6 (1%) 0 0 0 6 (1%)
Normal ALT, n (%) 604 (68%) 1 (17%) 26 (55%) 23 (68%) 654 (67%)
Mildly elevated (.42–100 U/L) 73 (8%) 0 2 (4%) 2 (6%) 77 (8%)
Mod. elevated (.100–1000 U/L) 11 (1%) 0 0 1 (3%) 12 (1%)
Severely elevated (.1000 U/L) 0 0 0 0 0
Missing 197 (22%) 5 (83%) 19 (8%) 8 (24%) 229 (24%)
*Malaria test performed only on symptomatic children, but no result in database not confirmation that asymptomatic.
{p-values only given when ,20% data missing. VBLL = venous blood lead level. RDT = rapid diagnostic test. MUAC=mid upper-arm circumference. Mod=moderately.
m=months. y = years. ALT = alanine transaminase.
doi:10.1371/journal.pone.0093716.t003
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neurological damage [21]. This variation may be due to a number
of factors including duration of exposure and other factors which
may influence absorption, storage, and effects of lead in the body
such as genetic polymorphisms [43], co-morbidities, and essential
trace element deficiency. The limited sensitivity and specificity of
the neurological assessments and categorisation may also have
contributed to the recorded variation.
A larger proportion of children with neurological features were
aged 1–3 years compared with those without neurological features.
The greatest proportion of high VBLLs were seen in children aged
1–,2 years, and the strongest association with neurological
features was in this age group after adjusting for VBLL. During the
initial outbreak investigation (before lead poisoning was confirmed
and before chelation therapy began) proportionally more children
aged 1–,2 years died amongst children displaying probable or
suspected neurological features. We hypothesise that this risk
pattern for both high VBLL and stronger association with
neurological features may reflect a number of factors: variation
in bioavailability of ingested lead; variation in exposure due to
behavioural (i.e., hand-mouth) and developmental factors; imma-
turity of the blood/brain barrier compared with older children
and possibly other age-related influences on activities and
movement around the contaminated villages and ore processing
areas. Conversely, there are several reasons why children younger
than 1 year may have been less at risk of raised VBLL and
neurological effects: shorter duration of potential exposure by
virtue of younger age; poorer mobility and less marked hand-
mouth behaviour; and physiological variation in absorption.
However, the neurological damage done by lead, beyond fatal
lead encephalopathy, is long-term [4,26] and only continued
monitoring will allow us to fully document and understand the
long-term sequelae of lead toxicity in this cohort.
Lead poisoning related to industrial activity is an ongoing
problem, with a recent outbreak in Senegal secondary to used lead
acid battery recycling linked to 18 child deaths and 81 additional
cases of poisoning [18]. In the United Nations-Administered
Province of Kosovo, camps for internally displaced people were
contaminated by industrial lead production, and children born
there between 1999 and 2007 had lead levels up to 74 mg/dL [44];
children near a recently closed auto-battery recycling plant in the
Dominican Republic had venous blood lead levels up to 130 mg/
dL [45]; and concerns continue about widespread exposure of
children to lead from industries in China [36,46]. Other heavy
metals such as mercury and cadmium also continue to cause
contamination [47] and poisoning associated with industrial
development [48,49]. With increased industrialisation in re-
source-poor countries and dumping of toxic waste, we expect
greater frequency of undetected lower level poisoning and an
increased risk of severe environmental toxicological emergencies.
Whilst the Zamfara outbreak was at the most severe end of the
spectrum, the true extent of lower-level poisoning and the
implications for those exposed are unclear.
Limitations to our data arise from the circumstance in which
they were collected, namely an emergency humanitarian response
to mass mortality and morbidity from lead poisoning. While
screening was offered to all children in the seven villages
remediated in the first year, tragically, hundreds of children had
died before the excess mortality was notified and cause identified
in these villages; these children were not included in this analysis.
In the first 2 months of the response, 42 children did not have
VBLL recorded immediately prior to starting chelation therapy
(with an earlier screening BLL $65 mg/dL) due to logistical
challenges, including three who had had witnessed seizures and
three with presumptive seizures; these children were not included
due to the likely effect of chelation on any VBLL taken after
therapy was started. Blood for VBLLs from these children were
taken 1–11 days after commencing chelation therapy; 70% were
still $80 mg/dL (range 15–241 mg/dL). Thus potentially some of
the most severely poisoned children were not included in this
analysis. The neurological data collected may have missed subtle
neurological abnormalities that would not have been identified
with the simple tools used that focused on detecting life-
threatening encephalopathy. The VBLLs in the first months
may not be precise due to the unanticipated need to determine
appropriate dilution methods for the portable testing equipment,
and because the Lead Care II will not be as precise as ICPMS.
However, quality control showed that Lead Care II values were on
average only 4.0 mg/dL lower than those measured using ICPMS.
In addition, the multivariable model was assessed for sensitivity to
excluding VBLL tests in the first months and the pattern of
Table 4. Final multi-level logistic regression model to assess factors associated with having any neurological features at time of
first-ever pre-chelation VBLL.
Unadjusted OR (95% CI) Adjusted OR (95% CI) p-value*
Age at time of VBLL ,0.001
0–,6 months 1.35 (0.36–5.04) 1.66 (0.44–6.31)
6–,12 months 2.07 (0.93–4.63) 1.46 (0.61–3.51)
1–,2 years 9.42 (5.23–16.96) 4.77 (2.50–9.11)
2–,3 years 3.54 (1.59–7.88) 2.69 (1.15–6.26)
3–5 years 1 1
VBLL ,0.001
45–64.9 1 1
65–79.9 1.21 (0.26–5.62) 1.02 (0.21–4.87)
80–99.9 3.06 (1.43–6.53) 2.75 (1.27–5.98)
100–119.9 4.87 (2.11–11.22) 3.84 (1.62–9.09)
120+ 38.77 (18.14–82.86) 22.95 (10.54–49.96)
*P-value from the Wald test of no association of the attribute with the outcome adjusted for the other variables in the model. VBLL = venous blood lead level. OR =odds
ratio. (n = 972).
doi:10.1371/journal.pone.0093716.t004
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associations were not substantially altered (data not shown).
Children with inadequately recorded neurological status at time of
VBLL had a lower geometric mean VBLL, which may indicate
that these children were less likely to have exhibited neurological
features. A sensitivity analysis of the model including all these
patients as having had no neurological features did not alter the
patterns of association (data not shown). The date of birth is often
inaccurate or unknown in this remote, rural region, therefore most
ages in this analysis are approximations, and thus age was
categorised. In addition there was a substantial amount of missing
data for some important variables such as the malaria RDT result.
The fact that only symptomatic children were tested suggests that
clinical malaria was present; however, as the RDT may be positive
for weeks after treatment, microscopy would be needed to confirm
acute infection. There is the potential that the neurological
features seen may be related to comorbidities other than malaria
or to permanent damage from previous high VBLLs. As with any
large dataset, despite standardised forms, continuous use of data
for clinical purposes, and regular data cleaning, it is possible that
there was some misclassification, but this is considered unlikely to
be differential. The strength of this dataset is its unequalled size,
severity of lead exposure, and scope of routinely collected clinical
data.
Conclusion
In this large cohort of 972 children exposed to environmental
lead contamination, 35% of children #5 years with a VBLL
requiring chelation therapy ($45 mg/dL) had VBLLs$80 mg/dL.
There was evidence that a VBLL $80 mg/dL was associated with
neurological features and strengthened as VBLL increased, and
neurological features were also more likely in children aged 1–,3
years compared to those 3–5 years. Severe neurological features
were seen at VBLL ,105 mg/dL only if there was a concurrent
positive malaria test, and among children tested for malaria, a
positive malaria RDT result was strongly associated with
neurological features after adjustment for age and VBLL. These
results will help clinicians managing children with lead poisoning
to determine which individuals are likely to be at greatest risk of
developing neurological features and therefore potentially life-
threatening encephalopathy. This is particularly important when
managing large outbreaks for determining urgency of therapy and
to help guide chelation protocols.
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